Published 2 days ago • loading... • Updated 19 hours ago

Hemostemix (CVE:HEM) Trading Down 19.4% – Here’s What Happened

Summary by themarketsdaily.com

Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded down 19.4% during trading on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares traded hands during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18. Hemostemix […]

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All

Left

Center

Right

watchlistnews.com

Hemostemix (CVE:HEM) Trading Down 19.4% – Here’s Why

Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 19.4% during trading on Wednesday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares changed hands during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18. Hemostemix Price Performance […]

19 hours ago

Read Full Article

tickerreport.com

Hemostemix (CVE:HEM) Shares Down 19.4% – What’s Next?

Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was down 19.4% during mid-day trading on Wednesday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares changed hands during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at […]

23 hours ago

Read Full Article

themarketsdaily.com

Hemostemix (CVE:HEM) Trading Down 19.4% – Here’s What Happened

2 days ago

Read Full Article

biotuesdays.com

Hemostemix Licences CytoImmune’s BioReactor Technologies - BioTuesdays

Hemostemix (TSXV:HEM; OTCQB:HMTXF) has announced that it has secured an arm’s length perpetual, royalty-free global license to CytoImmune’s BioReactor stem cell technologies. Subject to the TSXV Exchange acceptance, Hemostemix will pay CytoImmune $5,000,000 (twenty million shares) for the license. Hemostemix underscores that securing this license will provide the company with an economic and competitive advantage enabling it to scale its proprie…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year